NCT00941746

Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain

A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).

Conditions

• Osteoarthritis, Knee

Interventions

Type	Name	Description
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	PG110	Single, slow intravenous infusion
BIOLOGICAL	Placebo	Single, slow intravenous infusion that matches PG110 in appearance

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2009-07-20
• Last updated: 2011-06-07

Locations

1 site across 1 country: Netherlands